20 results about "Swine plague" patented technology

This invention belongs to the field of molecular marker technology, specifically relating to SNP molecular markers, primers, and applications of the PRRX2 gene associated with African swine fever virus (ASFV) antibody levels. The SNP molecular marker is located at 143 bp of exon 3 of the porcine PRRX2 gene (genotype XM_005654574.2), exhibiting T / C polymorphism. The nucleotide sequence of the SNP molecular marker is shown in SEQ ID NO.3. The molecular marker provided by this invention is closely associated with ASFV antibody levels in pigs. Compared to pigs with the TC / CC genotype at this locus, pigs with the TT genotype have higher ASFV antibody levels in their serum. This molecular marker can be applied to breed high-quality breeding pigs resistant to ASFV, thereby effectively improving the economic benefits of pig farming.

The invention belongs to the field of biology, and discloses a coating protein for diagnosis of an African swine fever virus antibody, application and a kit, and the coating protein comprises a p22 protein and an E199L protein; the amino acid sequence of the p22 protein is as shown in SEQ ID NO: 1, and the amino acid sequence of the E199L protein is as shown in SEQ ID NO: 3. The coating protein is composed of recombinant proteins of p22 and E199L, the two recombinant proteins can react with ASF positive serum and have good reactogenicity, and the detection kit based on the coating protein is high in detection precision, strong in specificity and good in repeatability.

The present disclosure provides a recombinant adenovirus for expressing African swine fever virus (ASFV) EP153R-EP402R protein and a construction method thereof, and belongs to the technical field of genetic engineering. In the present disclosure, a recombinant adenovirus vector pAD-CMV-EGFP-EP153R-EP402R is obtained through a series of intermediate processes using a recombinant adenovirus shuttle vector pENTRE-EGFP-TOPO; the recombinant adenovirus vector is linearized to transfect AD293 cells, a recombinant virus is screened according to cytopathy formed by adenovirus infection, an adenovirus packaging process is achieved, and the recombinant adenovirus for expressing ASFV EP153R-EP402R protein is obtained, laying a foundation for the construction of a recombinant adenovirus vaccine for expressing the ASFV EP153R-EP402R protein.

The invention relates to the technical field of prevention and treatment of porcine envelope virus infection, in particular to a pomegranate peel extract as well as a preparation method and application thereof, a composition for preventing and treating porcine envelope virus infection comprises the pomegranate peel extract, and porcine envelope virus comprises at least one of porcine epidemic diarrhea virus and African swine fever virus. The pharmaceutical composition has the effects of being good in prevention and treatment effect on diseases caused by PEDV and ASFV, high in safety and free of toxic and side effects.

Compounds that modulate the function, activity and / or expression of porcine leukocyte antigen complex II (SLA II) genes and / or SLA II proteins, use for medicine, use as medicaments or use for the treatment or prevention of ASF or ASFV infection are disclosed. The present disclosure also provides the use of the SLA-DMA, SLA-DMB, RFXANK, RFXAP5, and CIITA genes to achieve ASFV resistance.

The utility model provides a kind of enzyme label plate cleaning device for hog cholera virus detection, it is related to the field of cleaning technology, including workbench, the upper surface of workbench is equipped with two support columns, the outer surface of each support column is equipped with electric slide rail A, the outer surface of each electric slide rail A is slidably installed with sliding block A, the outer surface of two sliding blocks A is commonly equipped with electric slide rail B, the outer surface of electric slide rail B is slidably installed with sliding block B, the outer surface of sliding block B is equipped with shunt block, the bottom of shunt block is equipped with multiple cleaning spray heads;The utility model is equipped with electric slide rail A and electric slide rail B cooperation sliding block A sliding block B, realize the flexible movement of cleaning spray head in vertical and horizontal space, can accurately cover each hole site of enzyme label plate, avoid the problem that traditional fixed cleaning needs manual adjustment, ensure the consistency of enzyme label plate cleaning effect, significantly improve detection efficiency.

The application provides a preparation method and product of a full synthetic fiber F9 grade air filter material, and the preparation method comprises the following steps: a. taking raw materials of synthetic fibers and ultrafine fibers according to weight ratios, adding water into the mixed raw materials, mixing, and stirring and dispersing into a slurry; b. preparing a filter material from the slurry according to an existing wet forming method; c. after the filter material is dehydrated, acrylic resin liquid is coated on the surface of the filter material; and d. the filter material coated with the acrylic resin liquid is sequentially passed through three groups of drying cylinders, so that the water content of the dried filter material is less than 5%. The application provides a new type of filter material for filtering and isolating bacteria in air, and effectively solves the problem of African swine fever.

The invention provides the antibody specifically bound with the African swine fever virus CD2v protein and the application thereof, the antibody is high in titer and stable in property, can be bound with ASFV infected cells, and provides an important tool for ASFV detection, CD2v antigen or fragment detection and CD2v protein structure analysis.

The invention relates to the technical field of biology. The invention provides an African swine fever virus sample protection solution, which is characterized by comprising the following components in percentage by weight: 15 to 35 percent of guanidine isothiocyanate, 0.4 to 2.0 percent of sodium dodecyl sarcosinate, 0.8 to 3.0 percent of Ectoine, 0.1 to 0.5 percent of tris (2-carboxyethyl) phosphine hydrochloride, 0.2 to 0.8 percent of disodium ethylene diamine tetraacetate, 0.4 to 1.5 percent of sodium citrate and the balance of Tris-HCl buffer solution. The protection liquid can thoroughly inactivate viruses to guarantee safety, can resist high temperature, and effectively solves the problem of preservation of African swine fever samples at high temperature; meanwhile, the detection sensitivity of a sample treated by the protection liquid is better, and the accuracy is higher.

The invention relates to the technical field of porcine envelop virus infection prevention and treatment, in particular to application of hydroxytyrosol in preparation of drugs or feed additives for preventing and treating porcine envelop virus infection.The porcine envelop virus comprises at least one of porcine epidemic diarrhea virus, porcine reproductive and respiratory syndrome virus and African swine fever virus. The medicine or feed additive for preventing and treating swine envelope virus infection comprises hydroxytyrosol and auxiliary materials. The application has the effects of remarkably inhibiting envelope virus replication, reducing toxicity, overcoming the defects of vaccine immune failure, virus variation induced by antiviral drugs and the like, effectively reducing the morbidity and mortality of piglets, and being high in safety and free of toxic and side effects.

The invention provides the antibody specifically bound with the African swine fever virus CD2v protein and the application thereof, the antibody is high in titer and stable in property, can be bound with ASFV infected cells, and provides an important tool for ASFV detection, CD2v antigen or fragment detection and CD2v protein structure analysis.

A composition including modified ASFV outer-membrane protein antigen mutants (termed dominant negative toxoid antigens) that exhibit non-binding affinity to RBCs while inducing an antibody-mediated response capable of neutralizing unmodified proteins found on infectious outer-membrane-laden ASFV virions. A method for the treatment and / or prevention of ASFV by administering a dominant negative toxoid antigenic composition to animals, thereby averting RBC aggregation caused by the antigen and concurrently treating and / or preventing ASFV. An ASFV vaccine composition including dominant negative toxoid antigens. A composition including dominant negative toxoid antigens in conjunction together and in conjunction with antigens derived from capsid-based proteins, which collectively target both lysogenic and lytic viral replication cycles, thereby achieving optimal immune stimulatory protection. Methods and compositions allowing for differentiation of infected from vaccinated animals (DIVA).

The present invention belongs to the technical field of antiviral drugs. Provided is the use of thalicarpine in the preparation of an antiviral drug. The present invention demonstrates at the cellular level that thalicarpine has an inhibitory effect on a variety of viruses causing common infectious diseases in domestic pigs, especially having a significant inhibitory effect on the proliferation of African swine fever virus (ASFV), porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus type 2 (PCV2) and porcine epidemic diarrhea virus (PEDV) in vitro. Further disclosed in the present invention are an antiviral composition composed of an active ingredient, i.e. thalicarpine, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and / or excipient, and the use of the composition in the preparation of a viral infection inhibitor and / or in the preparation of a pharmaceutical preparation for preventing and / or treating a viral infectious disease, thereby providing a basis for the development of a new broad-spectrum antiviral drug.

Disclosed herein are recombinant antibodies or the fragments comprising a light chain variable (VL) domain and a heavy chain variable (VH domain) thereof for detecting African swine fever virus (ASFV). Also disclosed herein are kits comprising the recombinant antibodies, and methods of diagnosing the infection of ASFV by using the recombinant antibody or kit.

The application discloses application of phloretin in preparation of a medicine or a feed additive for treating or preventing porcine capsid virus infection, the medicine being phloretin or oral liquid, granules, tablets, powder prepared by adding a solvent or excipient with phloretin as an effective component, and a dosage being 2.5-10 mg / kg of pig body weight; or the phloretin being directly added into feed, and an adding amount being 0.01%-0.03% of the total weight of pig feed. The application takes phloretin or a composition containing phloretin as the medicine or the feed additive, is high in safety, free of toxic side effects, has a significant effect of inhibiting replication of capsid viruses such as porcine epidemic diarrhea virus, porcine reproductive and respiratory syndrome virus and African swine fever virus, reducing the virulence of porcine capsid virus, overcoming the disadvantages of possible immunization failure of vaccination and virus variation caused by use of antiviral drugs, effectively reducing the morbidity and mortality of piglets infected with porcine capsid virus, and having the effect of preventing and treating or preventing porcine capsid virus infection diseases.

The application discloses a CSFV-PPV bivalent subunit vaccine and a preparation method thereof. The vaccine comprises a first recombinant protein encoded by a first gene, a second recombinant protein encoded by a second gene and a pharmaceutically acceptable carrier. The first gene has a sequence shown in SEQ ID NO:1 or an increased or reduced sequence thereof. The second gene has a sequence shown in SEQ ID NO:2 or an increased or reduced sequence thereof. The application takes the antigen E2 protein of CSFV (CSFV) and the VP2 protein of PPV (PPV) as double targets, expresses the recombinant SC-E2 protein with a SpyCatcher label and the recombinant ST-VP2 protein with a SpyTag label in insect cells through a recombinant baculovirus vector, realizes in-vitro covalent assembly of the double antigens, and constructs the bivalent subunit vaccine which can simultaneously prevent and control two diseases, and has the advantages of high safety, strong immunogenicity, high prevention and control efficiency and easiness in large-scale production.

The present invention provides use of magnoline in the preparation of an antiviral drug, which belongs to the technical field of antiviral drugs. The present invention demonstrates at the cellular level that magnoline exhibits an inhibitory effect on various common infectious disease viruses in domestic pigs, especially in vitro exhibits a significant inhibitory effect on the proliferation of African swine fever virus (ASFV), porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus type 2 (PCV2), and porcine epidemic diarrhea virus (PEDV). Further disclosed in the present invention are an antiviral composition consisting of the active ingredient magnoline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and / or excipient, and use of the composition in the preparation of a viral infection inhibitor and / or in the preparation of a pharmaceutical formulation for preventing and / or treating viral infectious diseases, thereby providing a basis for the development of new broad-spectrum antiviral drugs.

A composition including modified ASFV outer-membrane protein antigen mutants (termed dominant negative toxoid antigens) that exhibit non-binding affinity to RBCs while inducing an antibody-mediated response capable of neutralizing unmodified proteins found on infectious outer-membrane-laden ASFV virions. A method for the treatment and / or prevention of ASFV by administering a dominant negative toxoid antigenic composition to animals, thereby averting RBC aggregation caused by the antigen and concurrently treating and / or preventing ASFV. An ASFV vaccine composition including dominant negative toxoid antigens. A composition including dominant negative toxoid antigens in conjunction together and in conjunction with antigens derived from capsid-based proteins, which collectively target both lysogenic and lytic viral replication cycles, thereby achieving optimal immune stimulatory protection. Methods and compositions allowing for differentiation of infected from vaccinated animals (DIVA).

This invention discloses a monoclonal antibody BY013 that binds to the African swine fever virus (ASFV) P30 protein and its applications. This invention provides an IgG antibody composed of a light chain and a heavy chain; CDR1, CDR2, and CDR3 in the variable region of the heavy chain are as shown in positions 47-54, 72-79, and 118-130 of SEQ ID NO: 1, respectively; CDR1, CDR2, and CDR3 in the variable region of the light chain are as shown in positions 49-60, 78-80, and 117-124 of SEQ ID NO: 3, respectively. This invention also protects the application of any of the above-described IgG antibodies in the preparation of products; the functions of the products are: binding to the ASFV P30 protein fragment; binding to the ASFV P30 protein; and binding to ASFV. The IgG antibody provided by this invention can be used for various applications such as Western blot, immunohistochemistry, flow cytometry, and ELISA, and can serve as an important tool for ASFV detection and structural analysis of the P30 protein.

An injectable, oral or nasal spray multivalent vaccine treats or prevents infection with a coronavirus, and / or influenza, and / or respiratory syncytial virus (RSV), or other viruses such as African swine fever virus (ASFV). The multivalent vaccine comprises a hybrid pseudovirus assembled from any of the following combinations of primary proteins: coronavirus S, and / or influenza HA and / or RSV fusion protein, and / or ASFV p12 plus any of the following secondary proteins from either: coronavirus N, M, and E, and / or Influenza NA,M1,M2 and NP and / or RSV Matrix, G, and Nucleocapsid, and / or ASFV p35, p27, p14. These hybrid pseudoviruses package an alphaviral vector carrying RNA encoding multiple receptor binding domain regions of the attachment or fusion proteins of these viruses, wherein the hybrid pseudovirus and alphaviral vector are combined in an injectable, oral, or nasal spray formulation.